Literature DB >> 19054604

Thirty-day mortality after nephrectomy: clinical implications for informed consent.

Vincent Cloutier1, Umberto Capitanio, Laurent Zini, Paul Perrotte, Claudio Jeldres, Shahrokh F Shariat, Philippe Arjane, Jean-Jacques Patard, Francesco Montorsi, Pierre I Karakiewicz.   

Abstract

BACKGROUND: The existing literature suggests that the surgical mortality (SM) observed with nephrectomy for localised disease varies from 0.6% to 3.6%.
OBJECTIVE: To examine age- and stage-specific 30-d mortality (TDM) rates after partial or radical nephrectomy. DESIGN, SETTING, AND PARTICIPANTS: We relied on 24535 assessable patients from the National Cancer Institute (NCI) Surveillance, Epidemiology, and End Results (SEER) database. MEASUREMENTS: In 12283 patients, logistic regression models were used to develop a tool for pretreatment prediction of the probability of TDM according to individual patient and tumour characteristics. External validation was performed on 12252 patients. RESULTS AND LIMITATIONS: In the entire cohort of 24535 patients, 219 deaths occurred during the initial 30 d after nephrectomy (0.9% TDM rate). TDM increased with age (≤49 yr: 0.5% vs 50-59 yr: 0.7% vs 60-69 yr: 0.9% vs 70-79 yr: 1.2% vs ≥80 yr: 2.0%; χ(2) trend p<0.001) and stage (0.3% for T1-2N0M0 vs 1.3% for T3-4N0-2M0 vs 4.2% for T1-4N0-2M1; χ2 trend p=<0.001). TDM decreased in more recent years (1988-1993: 1.3% vs 1994-1998: 0.9% vs 1999-2002: 0.7% vs 2003-2004: 0.6%; χ2 trend p<0.001) and was lower after partial versus radical nephrectomy (RN) (0.4% vs 0.9%; p=0.008). Only age (p<0.001) and stage (p<0.001) achieved independent predictor status. The look-up table that relied on the regression coefficients of age and stage reached 79.4% accuracy in the external validation cohort.
CONCLUSIONS: Age and stage are the foremost determinants of TDM after nephrectomy. Our model provides individual probabilities of TDM after nephrectomy, and its use should be highly encouraged during informed consent prior to planned nephrectomy.

Entities:  

Mesh:

Year:  2008        PMID: 19054604     DOI: 10.1016/j.eururo.2008.11.023

Source DB:  PubMed          Journal:  Eur Urol        ISSN: 0302-2838            Impact factor:   20.096


  12 in total

1.  Cytoreductive nephrectomy in the modern era: Predictors of use, morbidity, and survival.

Authors:  Brian J Minnillo; William Tabayoyong; John J Francis; Matthew J Maurice; Hui Zhu; Simon Kim; Robert Abouassaly
Journal:  Can Urol Assoc J       Date:  2017-05-09       Impact factor: 1.862

Review 2.  The role of surgery for metastatic renal cell carcinoma in the era of targeted therapies.

Authors:  Pierre Bigot; Souhil Lebdai; Alain Ravaud; Abdel Rahmène Azzouzi; Jean-Marie Ferrière; Jean-Jacques Patard; Jean-Christophe Bernhard
Journal:  World J Urol       Date:  2013-03-30       Impact factor: 4.226

3.  Patient and disease factors predictive of adverse perioperative outcomes after nephrectomy.

Authors:  J M Henderson; D Pitcher; R Steenkamp; S Fowler; F X Keeley
Journal:  Ann R Coll Surg Engl       Date:  2016-05       Impact factor: 1.891

Review 4.  Cytoreductive nephrectomy and its role in the present-day period of targeted therapy.

Authors:  Stephen H Culp
Journal:  Ther Adv Urol       Date:  2015-10

5.  Benefit in regionalization of care for patients treated with nephrectomy: a Nationwide Inpatient Sample.

Authors:  Andreas Becker; Marco Bianchi; Jens Hansen; Zhe Tian; Shahrokh F Shariat; Ioana Popa; Paul Perrotte; Quoc-Dien Trinh; Pierre I Karakiewicz; Maxine Sun
Journal:  World J Urol       Date:  2014-02-11       Impact factor: 4.226

6.  Age--an independent prognostic factor of clinical outcome in renal malignancies: results of a large study over two decades.

Authors:  Marie C Hupe; Axel S Merseburger; Vinata B Lokeshwar; Hendrik Eggers; Hendrik Rott; Gerd Wegener; Mahmoud Abbas; Markus A Kuczyk; Thomas R Herrmann
Journal:  World J Urol       Date:  2013-10-02       Impact factor: 4.226

7.  Comparison of Immediate vs Deferred Cytoreductive Nephrectomy in Patients With Synchronous Metastatic Renal Cell Carcinoma Receiving Sunitinib: The SURTIME Randomized Clinical Trial.

Authors:  Axel Bex; Peter Mulders; Michael Jewett; John Wagstaff; Johannes V van Thienen; Christian U Blank; Roland van Velthoven; Maria Del Pilar Laguna; Lori Wood; Harm H E van Melick; Maureen J Aarts; J B Lattouf; Thomas Powles; Igle Jan de Jong Md PhD; Sylvie Rottey; Bertrand Tombal; Sandrine Marreaud; Sandra Collette; Laurence Collette; John Haanen
Journal:  JAMA Oncol       Date:  2019-02-01       Impact factor: 31.777

8.  Risk-adjusted outcomes in Medicare inpatient nephrectomy patients.

Authors:  Donald E Fry; Michael Pine; Susan M Nedza; David G Locke; Agnes M Reband; Gregory Pine
Journal:  Medicine (Baltimore)       Date:  2016-09       Impact factor: 1.889

9.  Reorganising specialist cancer surgery for the twenty-first century: a mixed methods evaluation (RESPECT-21).

Authors:  Naomi J Fulop; Angus I G Ramsay; Cecilia Vindrola-Padros; Michael Aitchison; Ruth J Boaden; Veronica Brinton; Caroline S Clarke; John Hines; Rachael M Hunter; Claire Levermore; Satish B Maddineni; Mariya Melnychuk; Caroline M Moore; Muntzer M Mughal; Catherine Perry; Kathy Pritchard-Jones; David C Shackley; Jonathan Vickers; Stephen Morris
Journal:  Implement Sci       Date:  2016-11-25       Impact factor: 7.327

Review 10.  Surgical Management of Advanced and Metastatic Renal Cell Carcinoma: A Multidisciplinary Approach.

Authors:  Brian M Shinder; Kevin Rhee; Douglas Farrell; Nicholas J Farber; Mark N Stein; Thomas L Jang; Eric A Singer
Journal:  Front Oncol       Date:  2017-05-31       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.